louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06666959: Sevoflurane Versus Propofol in Endovascular Coiling of Cerebral Aneurysm
Official title: Comparison of the Neuroprotective Effect of Sevoflurane Versus Propofol in Patients Undergoing Endovascular Coiling of Cerebral Aneurysm
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Propofol
Sevoflurane
Lead sponsor: Tongji Hospital
Sponsor class: OTHER
First posted: 2024-10-31
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: In Tongji hospital

Brief summary: The goal of this observational study is to learn about the anti-inflammatory effects of anesthetics on patients undergoing endovascular coiling of cerebral aneurysm. The main question it aims to answer is:

Does sevoflurane or propofol affect the inflammatory response in subarachnoid hemorrhage?

Participants already undergoing endovascular coiling of cerebral aneurysm will have their serum levels of inflammatory factors measured.


Eligibility criteria: Inclusion Criteria:

* Consecutive patients aged 18 years and older presenting to the Tongji hospital for endovascular coiling of cerebral aneurysm were eligible for enrollment.

Exclusion Criteria:

* have an endocrine system disease
* pregnancy
* have other brain disorders
* take drugs that alter endocrine hormones
* receive perioperative blood derivatives

Primary outcomes:
measure: Concentration of interleukin-10
timeFrame: From enrollment to 3 months postoperation
Secondary outcomes:
measure: Concentration of interleukin-1
timeFrame: From enrollment to 3 months postoperation
measure: Concentration of interleukin-2
timeFrame: From enrollment to 3 months postoperation
measure: Concentration of interleukin-6
timeFrame: From enrollment to 3 months postoperation
measure: Concentration of interleukin-8
timeFrame: From enrollment to 3 months postoperation
measure: Concentration of tumor necrosis factor
timeFrame: From enrollment to 3 months postoperation
measure: Concentration of S100B
timeFrame: From enrollment to 3 months postoperation
measure: length of stay
timeFrame: through study completion, an average of 6 months
measure: costs
timeFrame: through study completion, an average of 6 months
measure: Glasgow Coma Score
timeFrame: From enrollment to 3 months postoperation
Other outcomes:
Locations:
city: Wuhan
country: China
facility: Department of Neurosurgery
state: Hubei
Study officials:
References:
Clinical trial NCT05988359: Quantitative Evaluation of Aerosols Produced in the Dental Office
Official title: Assessment of Aerosol Quantity Generated During Caries Treat-ment With Er:YAG Laser. A Randomized Clinical Trial.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Aerosol Disease
Caries,Dental
Keywords: laser
Er:YAG
disinfection
bacteria
high-volume evacuator
Lead sponsor: Wroclaw Medical University
Sponsor class: OTHER
First posted: 2023-08-14
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Background: Maintaining biosafety in dental practice requires an efficient elimination of aerosols produced during dental treatment. The objective of this research was to assess the quantity of aerosols and aerobic bacteria present in the air during the treatment of caries. Methods: This study was divided into two groups based on the caries treatment method involving 60 patients with 60 m olar teeth (n=60) in the mandible. Group 1 (n=30) received a conventional dental turbine W\&H Synea TA-98LC (W\&H, Bürmoos, Austria), while Group 2 (n=30) received an Er:YAG laser (LightWalker, Fotona, Slovenia). Measurements of aerosol particles between 0.3 - 10.0 μm near the operator's mouth were taken using the PC200 laser particle counter (Trotec GmbH, Schwerin, Germany). The number of aerobic bacteria in the air was determined using 60 micro-biological plates with a microbiological medium (Columbia Agar with 5% Sheep Blood) and the sedimentation method. A control group G3 was established to measure the initial aero-sol level and the initial total number of bacteria CFUs (colony-forming units) before each treatment.


Eligibility criteria: Inclusion Criteria:

- The subjects were chosen for the study under the subsequent inclusion criteria: occurrence of medium or profound caries on Black class I, ICDAS 3,4

Exclusion Criteria:

* Patients with systematic diseases that can influence the treatment of periodontitis
* Patients under or took antibiotics 2 months.
* Patients under or took immunosuppressors the last 6 months.
* Pregnant or lactating woman.

Primary outcomes:
measure: Aerosols measurment
timeFrame: immediately before the procedure
measure: Aerosols measurment
timeFrame: immediately after the procedure
Secondary outcomes:
measure: Bacteriological study
timeFrame: 60 miniutes before the procedure
measure: Bacteriological study
timeFrame: immediately before the procedure
measure: Bacteriological study
timeFrame: immediately after the procedure
Other outcomes:
Locations:
city: Wroclaw
country: Poland
facility: Oral Surgery Department
Study officials:
References:
Clinical trial NCT00205959: LPHP-Philos-PHN Conservative Treatment
Official title: Comparison of Standard Treatment Methods for Proximal Humerus Fractures
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Proximal Humeral Fracture
Keywords: Humerus
Fractures
Locking Plates
Nail System
Lead sponsor: AO Innovation Translation Center
Sponsor class: OTHER
Collaborators: name: Synthes Inc.
name: AO Research Fund
First posted: 2005-09-21
Enrollment: 640
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The aim of the study is to compare the results regarding fracture healing

and functional outcome after the treatment of proximal humeral fractures

with the four different treatment methods after 12w./6months and 12 months

based on radiological evaluation as well as the "constant score" and the

"neer score".

Detailed description: Evaluation of proximal humeral fractures using a new stable-angled implant.

Eligibility criteria: Inclusion Criteria:

* fractures of proximal humerus
* age over 18 years
* completed skeletal development
* fracture less than 5 days old

Exclusion Criteria:

* open fractures
* pseudoarthrosis, pathological or refractures
* ipsilateral fractures of distal humerus or elbow
* polytraumatic conditions
* pregnancy
* subject with known history of diseases that influence the healing process
* alcohol, drug abuse

Primary outcomes:
measure: Radiological comparison of the fracture healing
measure: Functional outcome based on "constant and neer score" after 12 months
Secondary outcomes:
measure: Analysis of occured complications
measure: Radiological evaluation of possible misallocation
measure: Subjective patient judgement of before and after treatment according to DASH-questionnaire
Other outcomes:
Locations:
city: Freiburg
country: Germany
facility: Universitaestklinik Freiburg, Klinik für Traumatologie
Study officials:
affiliation: Universitaetsklinik Freiburg
name: Norbert Südkamp, Prof. MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04269759: 145/5000 Oral State and Knowledge, Attitudes and Practices of Pregnant Women on Their Oral Health and That of Their Unborn Child
Official title: Oral State and Knowledge, Attitudes and Practices of Pregnant Women on Their Oral Health and That of Their Unborn Child
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Dental Care
Keywords: prevention
dental care
pregnancy
Lead sponsor: University Hospital, Bordeaux
Sponsor class: OTHER
First posted: 2020-02-17
Enrollment: 117
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Pregnant women

Brief summary: Pregnancy is a physiological condition which is accompanied by changes in the oral sphere which may increase the need for oral care and prevention. The role of dental surgeons is to provide appropriate care and to provide information on the prevention of oral diseases of pregnant women but also of their unborn baby.

Investigators wants to determine if pregnants women know that national health insurance has set up a free dental care preventive examination.

Detailed description: Investigators will describe the knowledge, attitudes and practices of pregnant women consulting at the maternity of Bordeaux University Hospital with regard to the oral examination of health insurance.

This study will also Evaluate the care needs and the acceptability of oral screening and study the association between the use of prenatal health insurance and dental health.

Eligibility criteria: Inclusion Criteria:

* Pregnant women

Exclusion Criteria:

* Patient refuses to participate in the study.
* Persons under guardianship
* No understanding of oral French.
* People with decompensated severe psychiatric disorder or severe cognitive impairment.

Primary outcomes:
measure: Use of prenatal health insurance for free dental examination
timeFrame: Enrollment
Secondary outcomes:
Other outcomes:
Locations:
city: Bordeaux
country: France
facility: CHU de Bordeaux
Study officials:
References:
Clinical trial NCT01035359: Intraarticular Distal Radius Fractures, X-fix or Volar Fixation
Official title: Dorsally Displaced Intraarticular Distal Radius Fractures - Volar Plate or External Fixation. A Prospective Randomized Trial.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dorsally Displaced Intraarticular Distal Radius Fractures
Age 50 - 74 for Females or 60-74 for Males
Low Energy Trauma
Keywords: radius
fracture
wrist
external
fixation
volar
plate
DASH
PRWE
Lead sponsor: Karolinska Institutet
Sponsor class: OTHER
First posted: 2009-12-18
Enrollment: 70
Sex: ALL
Minimum age (years): 50
Maximum age (years): 74
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Distal radius fractures are treated surgically if severely displaced. This study aims to investigate the outcome after surgery. The investigators will randomize patients to either external fixation with optional addition of k-wires or open reduction and fixation with a volar plate.

Detailed description: This study has been merged with NCT 01034943 and a new permit has been issued by the Swedish National board on Ethical Permits

Eligibility criteria: Inclusion Criteria:

* Female 50-74 years or male 60-74 years
* Dorsally displaced intraarticular distal radius fracture
* Dorsal angulation \>20 degrees measured from the plane perpendicular to the radius axis
* Low energy trauma
* Injury \<72 hours when diagnosed
* Patient independent of help for ADL

Exclusion Criteria:

* Earlier dysfunction in any wrist
* Other major injuries
* Rheumatoid arthritis or other systemic joint disease
* Dementia or severe psychiatric disease
* Severe medical condition making general anesthesia a major risk

Primary outcomes:
measure: The primary outcome is measured by DASH (Disability of the Arm, Shoulder and Hand), which is a self administered questionnaire validated for disease and dysfunction of the upper limb.
timeFrame: 12 months
Secondary outcomes:
measure: A secondary outcome is the degree of malalignment on the x-ray of the injured wrist.
timeFrame: 12 months
measure: A secondary outcome of this study is the EQ5D, which is a validated quality-of-life instrument.
timeFrame: 12 months
Other outcomes:
Locations:
city: Stockholm
country: Sweden
facility: Stockholm South Hospital Department of Orthopeadic Surgery
Study officials:
References:
Clinical trial NCT00191659: Study of Broader Efficacy of Atomoxetine in the Treatment of ADHD in Children/Adolescents
Official title: A Randomised, Controlled, Open-Label Study of the Broader Efficacy of Atomoxetine Hydrochloride in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Attention Deficit Hyperactivity Disorder
Lead sponsor: Eli Lilly and Company
Sponsor class: INDUSTRY
First posted: 2005-09-19
Enrollment: 200
Sex: ALL
Minimum age (years): 7
Maximum age (years): 15
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To test the hypothesis that children/adolescents with ADHD, who are treated with atomoxetine hydrochloride in comparison to standard current therapies have greater improvements in their quality of life.


Eligibility criteria: Inclusion Criteria:

* Diagnosis of ADHD

Exclusion Criteria:

* Patients who weigh less than 20kg at visit 1
* Have Bipolar Disorder/seizure disorder/taken anticonvulsants for seizures
* Judged to be at suicidal risk
* Taking psychotropic medication on a regular basis
* Hypertension

Primary outcomes:
measure: To test whether atomoxetine given for 10 weeks is superior to standard current therapy as measured by CHIP-CE (Child Health and Illness Profile - Child Edition)
Secondary outcomes:
measure: CHIP-CE total mean score after 4 weeks of treatment.
measure: The domains of the CHIP-CE after 4 and 10 weeks of treatment.
measure: The following are measured after both 4 and 10 weeks of treatment:
measure: Family Buden of Illness
measure: Harter Self Perception Profile
measure: ADHD-RS
measure: Clinical Global Impression- Severity
measure: Clinical Global Impression -Improvement
measure: To assess whether changes to the above scales are maintained over long term
measure: Long-term safety of atomoxetine
Other outcomes:
Locations:
city: Basingstoke
country: United Kingdom
facility: For additional information regarding investigative sites for this trial, please call 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559), Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
state: Hampshire
Study officials:
affiliation: Eli Lilly and Company
name: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST)
role: STUDY_DIRECTOR
References:
Clinical trial NCT00514059: Immunogenicity and Safety Study of a Booster Dose (5th) of Diphteria-Tetanus-Pertussis-Polio Vaccine
Official title: Open Clinical Study to Assess the Immune Response and Safety of a Booster Dose (5th Dose) of a Combination Vaccine Against Diphteria-Tetanus-Pertussis-Polio Given to Healthy Adolescents 15-16 Years of Age.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Diphtheria
Tetanus
Pertussis
Polio
Keywords: Diphteria-tetanus-pertussis-polio vaccine
Booster immunization
Vaccine effect (Diphtheria-tetanus-acellular pertussis-polio)
Immunity
Safety
Lead sponsor: Norwegian Institute of Public Health
Sponsor class: OTHER_GOV
First posted: 2007-08-09
Enrollment: 83
Sex: ALL
Minimum age (years): 15
Maximum age (years): 16
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: An open clinical trial to study the immune response and safety after giving a booster dose (5th Dose) of a combination vaccine against Diphteria-Tetanus-Pertussis-Polio to healthy adolescents 15-16 Years of age. The first three doses were given during the first year of life, according to the Norwegian child immunization program. The fourth dose was given in a previous clinical trial performed in 1998 when the children were 6-7 years old.

In 2006 there was a change in the child immunization program in Norway: a fourth dose of a Combination Vaccine Against Diphteria-Tetanus-Pertussis-Polio is given to children 6-7 years old.

This study will give us information if there is need for an additional dose (5th dose) of a combination vaccine, containing the pertussis components, before the adolescents are leaving secondary school.


Eligibility criteria: Inclusion Criteria:

* Healthy adolescents who have previously received a dose of a vaccine against diphteria, tetanus, pertussis and polio in a clinical trial in 1998
* Written informed consent from the adolescent and one of his/her parents
* The family must understand norwegian

Exclusion Criteria:

* Serious chronic diseases
* Vaccination against tetanus last 12 months
* Immunization with a Diphteria vaccine component after the study in 1998
* Suspected or confirmed immune deficiency
* Immunological/immunosuppressive treatment
* Pregnancy
* Serious reactions to previous immunization with any of the vaccine components
* Acute fever (axillary temperature ≥ 38°C) at the the of vaccination. (Postpone vaccination)

Primary outcomes:
measure: To measure vaccine specific antibody responses after a fifth dose of a combination vaccine against diphteria-tetanus-pertussis-polio. To register local and systemic reactions after vaccination.
Secondary outcomes:
measure: To measure vaccine specific antibody responses approximately eight years after a fourth dose of a combination vaccine against diphteria-tetanus-pertussis-polio.
Other outcomes:
Locations:
city: Oslo
country: Norway
facility: Norwegian Institute of Public Health
Study officials:
affiliation: Norwegian Institute of Public Health
name: Synne Sandbu, Physician
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01443559: Xenogenic Keratoplasty From Porcine Cornea
Official title: Phase I Study of Xenogenic Keratoplasty From Porcine Cornea in the Treatment of Infectious Corneal Ulcer
Study type: INTERVENTIONAL
Overall status: SUSPENDED
Phase: PHASE1
Conditions: Porcine Corneal Xenograph
Keywords: Xenogenic
Lead sponsor: Xiamen University
Sponsor class: OTHER
First posted: 2011-09-29
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Acellular porcine cornea is a valid substitution for human cornea because of its similar biological structure, corneal superficial curvature and good histocompatibility toward human. Facing the lack of human cornea donor, it is hypothesised that using acellular lamellar porcine cornea as an alternative of lamellar human cornea to treat infectious corneal ulcer.

Detailed description: Acellular porcine cornea eligibility criteria:

1. fresh porcine cornea,
2. porcine cornea keeping transparent without scar, neovascularization or corneal ulcer,
3. porcine cornea keeping integrative corneal epithelium and endothelium,
4. acellular porcine cornea keeping transparent.

Eligibility criteria: Inclusion Criteria:

* Patients with severe infectious corneal ulcer
* The ulcers can not be controlled with existing antibiotics eye drops or medicine after 1 week treatment
* The infected corneas have risks of penetrating
* The depth of ulcers are less than 400um
* The bridge of the ulcers is away from corneal limbal more than 1mm
* Patients aged 18 or older
* Patients able and willing to sign the informed consent form

Exclusion Criteria:

* Patients with severe infectious corneal ulcer in stable stage
* Patients with corneal ulcers after viruses infection, such as herpes simplex virus
* Patients with corneal ulcers from non-infectious factors, such as toxicity, burn or immunological inflammation
* The ulcers are not cover pupil zone and will not result in visional defect in future
* The depth of ulcer is less than 50um
* Patients has history of keratoplasty surgery

Primary outcomes:
measure: Rate of rejection in three months after keratoplasty
timeFrame: three months after lamellar keratoplasty
Secondary outcomes:
measure: Density of regenerative sub-epithelial nerve plex, stromal nerve and stromal keratocytes in vivo confocal microscopy
timeFrame: one year
Other outcomes:
Locations:
city: Xiamen
country: China
facility: Xiamen University Affiliated Xiamen Eye Center
state: Fujian
Study officials:
affiliation: Eye Institute of Xiamen University
name: Zuguo Liu, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT00859859: Vagus Nerve Stimulation in Rheumatoid Arthritis
Official title: Vagus Nerve Stimulation in Rheumatoid Arthritis
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Rheumatoid Arthritis
Lead sponsor: Northwell Health
Sponsor class: OTHER
First posted: 2009-03-11
Enrollment: 23
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to examine the short-term effects of vagus nerve stimulation (VNS) by auricular stimulation (stimulation of the auricular branch of the vagus nerve which innervates the ear) in rheumatoid arthritis (RA). RA is characterized by a chronic systemic inflammation affecting the joints but also carries an increased risk for extra-articular manifestations as well as other organ manifestations such as cardiovascular disease (CVD), which significantly contributes to morbidity and mortality in this disorder.


Eligibility criteria: Inclusion Criteria:

1. Patients with a diagnosis of RA based on the ACR guidelines. Disease activity measured as activity score (DAS-28 CRP) will be used
2. None of the exclusion criteria (see below).

Exclusion Criteria:

1. Minors (\<18 years of age) and mentally incompetent individuals
2. One or more of the following conditions: immunosuppressive condition (which includes malignancy, chronic alcoholism, diabetes), severe chronic dementia, psychiatric illness with active psychosis, current intravenous or other serious illicit drug use
3. Pregnancy
4. Terminal status referred for palliative care only
5. Homeless status
6. IDDM and NIDDM patients will not be enrolled in this study
7. Previous history of ischemic cardiovascular disease including myocardial infarction, unstable angina, and bradytachyarrythmias
8. Moderate or severe anemia. Hemoglobin levels will be determined at screening. A cut-off level of \< 10 mg/dL in women and \< 11 mg/dL in men is selected.
9. Smoking
10. Subjects taking concomitant medications potentially affecting autonomic function such as anti-cholinergic medications and beta-blockers.

Primary outcomes:
measure: Assessment of short-term and medium-term effects of vagus nerve intervention with endpoints such as autonomic function, cytokine synthesis, inflammatory markers as well as disease activity score and global health measurement in subjects
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Manhasset
country: United States
facility: The Feinstein Institute for Medical Research
state: New York
Study officials:
affiliation: Northwell Health
name: Kevin J Tracey, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Addorisio ME, Imperato GH, de Vos AF, Forti S, Goldstein RS, Pavlov VA, van der Poll T, Yang H, Diamond B, Tracey KJ, Chavan SS. Investigational treatment of rheumatoid arthritis with a vibrotactile device applied to the external ear. Bioelectron Med. 2019 Apr 17;5:4. doi: 10.1186/s42234-019-0020-4. eCollection 2019.